A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)
Latest Information Update: 20 Jun 2024
At a glance
- Drugs Miricorilant (Primary)
- Indications Weight gain
- Focus Therapeutic Use
- Acronyms GRATITUDE 2; GRATITUDE II
- Sponsors Corcept Therapeutics
Most Recent Events
- 06 Feb 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2022 According to a Corcept Therapeutics media release, data from this study will present at a medical conference next year
- 15 Feb 2022 According to a Corcept Therapeutics media release, data from the study is expected in fourth quarter 2022.